|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Antibacterials - Regulations, Resistance & Generics
Datamonitor, Sep 2004, Pages: 203
Antibacterial players are currently facing significant hurdles in terms of increasing and maintaining product revenue.
These include growing resistance across classes, greater restrictions relating to the use of antibacterials and an expected increase in generic competition following the expiry of a number of key patents in the next 2-3 years.
Scope of report:
In-depth analysis of country-specific environmental factors that affect the performance of antibacterial products
Review of recent and expected product specific events and other aspects that will impact sales of leading products
Country-specific sales forecasts to 2014 of leading brands and classes, for each for the seven major markets
Detailed case-study analysis of life-cycle management strategies such as follow-up products and reformulations
Highlights:
Increased regulatory scrutiny, drug resistance and generic competition have placed greater pressure on antibacterial profit margins. This explains the lack of significant activity in the current antibacterial pipeline. We predict that, by 2014, pipeline compounds will only account for 10.9% of total antibacterial revenue.
Regulatory scrutiny and pharmacovigilance responsibilities are becoming ever more intense. Key players should support initiatives aimed at easing product approval processes and should also tighten compliance practices throughout their businesses in order to reduce the risk of heavy fines and reductions to ROI.
Novel formulations can allow access to additional market segments while even minor clinical advantages can drive uptake of follow-ups, provided they are accompanied by improvements in cost-efficiency. We believe that key players will need to increase their focus on such activities in order to maintain their market position.
Reasons to Purchase:
Quantify future size and scope of the antibacterial market and potential for new products
Understand key drivers and predict the future performance of key compounds
Evaluate a range of lifecycle-management strategies to combat the threat of generic incursion
Customers who bought this item also bought
Commercial Insight: Antibacterials - Regulations, Resistance & Generics
Commercial Insight: Antibacterials - Pharma Strikes Antibac
US and European Prescription Generic Markets: An Examination of Commercial and Regulatory Contrasts
Commercial Insight: Antipsychotics - From Blockbuster Brands to Billion Dollar Generics
Mylan Laboratories Generics Company Intelligence Report
Watson Pharmaceuticals Generics Company Intelligence Report
Global Generics Guide 3rd Edition: Benchmarking Generics Company Capabilities and Strategy
The Generics Industry in 2005: A New Threat to Pharma
|
|
|
|
